color

Sample Report

COVID-19 test

PATIENT Jane Doe

DOB: May 25, 1977
Sex: Female

ID: 123456

ORDERING PHYSICIAN

Dr. Jenny Jones
Sample Medical Group
123 Main St.
Sample, CA

SPECIMEN

Type: Nasopharyngeal
Barcode: 223 234234 2343
Collected: Mar 24, 2020
Received: Mar 24, 2020

Report date: March 25, 2020

NEGATIVE for SARS-CoV-2.

This means that SARS-CoV-2 (the virus that causes COVID-19) was not detected in the patient's sample collected on March 24, 2020.

Variability in collection technique can reduce the sensitivity of the test, and SARS-CoV-2 may not be detected in early stages of infection. False negatives are possible. If patient is experiencing symptoms, consider collecting a new sample for COVID-19 testing or testing for other respiratory viruses. Collection of multiple specimens may be necessary to detect the SARS-CoV-2 virus.

DETAILS

TEST	RESULTS
SARS-CoV-2 amplification test	NEGATIVE (Not Detected)

To learn more about the technical details of this test, visit color.com/covid19-details.

HELPFUL INFORMATION FOR PATIENT

Because it is possible for this test to give a false negative in some people with COVID-19, if you have symptoms of illness (such as fever, cough, and/or shortness of breath), you should discuss your symptoms and your test results with your doctor who can decide how to care for you. The CDC recommends that individuals experiencing the following symptoms get medical attention immediately:

- Trouble breathing
- Persistent pain or pressure in the chest
- New confusion or inability to arouse
- Bluish lips or face

The CDC has provided useful information on how to protect yourself and others. The CDC has also provided information on when to seek medical attention. Key points are outlined below for your reference, and you can find this information at https://www.cdc.gov/coronavirus/2019-ncov.

If you are a healthcare professional, first responder, or frontline worker who believes you have been directly exposed while at work, consider contacting your place of work

HELPFUL INFORMATION FOR PATIENT
(Continued)

for specific occupational health guidance about whether to stay home or continue working. Recommendations set forth by your employer or the Department of Health may differ from the CDC's guidelines.

CDC: FOR PEOPLE WHO ARE SICK

- The CDC recommends that if you are or might be sick with COVID-19 stay home except to get medical care, and avoid using public transportation if you must leave your home.
- Separate yourself from other people in your home as much as possible.
- Wear a facemask if you are around other people. If a facemask is unavailable, you may use a bandana or scarf to cover your mouth and nose. If you feel too short of breath to wear a mask, alert those around you so that they may wear a mask.
- Cover your coughs & sneezes with a tissue, clean your hands often with soap and water for at least 20 seconds, and avoid sharing household items (for example, utensils, towels, glasses) as much as possible.
- Clean all 'high-touch' surfaces in your home frequently.
- **Please work with your provider to determine appropriate next steps, including when to end self-isolation.**
- Learn more at https://www.cdc.gov/coronavirus/2019-ncov.

This test is only for use under the Food and Drug Administration's Emergency Use Authorization, but is not FDA cleared or approved. This laboratory developed test has been validated in accordance with CLIA and the FDA's Guidance Document (Policy for Diagnostic Tests for Coronavirus Disease-2019 during the Public Health Emergency Immediately in Effect Guidance for Clinical Laboratories, Commercial Manufacturers, and Food and Drug Administration Staff Document) issued on March 16, 2020. As per the EUA application process, validation data has been submitted to the FDA. FDA's independent review of this validation data is pending. This test is only authorized by FDA for the duration of time the declaration that circumstances exist justifying the authorization of the emergency use of laboratory developed tests for detection of SARS-CoV-2 virus and/or diagnosis of COVID-19 infection under section 564(b)(1) of the Act, 21 U.S.C. 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.